文献速递妇科产科

晚期卵巢癌间歇性减瘤术联合或不联合腹腔热灌注化疗后的吻合口漏

Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer.
PubMed 文献 · Gynecol Oncol · 2021-07-09

这项回顾性队列研究纳入了61例III/IV期高级别卵巢癌患者,比较接受新辅助化疗后间歇性减瘤术(IDS)联合结直肠切除+腹腔热灌注化疗(HIPEC)与单纯IDS的吻合口漏发生率。结果显示,HIPEC组吻合口漏发生率为9.5%,非HIPEC组为7.5%,差异无统计学意义(p=0.99);但发生吻合口漏的患者总生存期显著缩短(9.4 vs 40.6个月,p=0.013)。

要点

  • HIPEC不增加IDS联合结直肠切除术后吻合口漏风险(9.5% vs 7.5%,p=0.99)。
  • 吻合口漏与总生存期显著缩短相关(9.4 vs 40.6个月,p=0.013)。
  • HIPEC本身不应成为拒绝结直肠切除或决定结肠转流的依据。

核心结论

  • 在晚期卵巢癌患者中,IDS联合结直肠切除和再吻合时,HIPEC与吻合口漏风险增加无关。

研究设计与样本

  • 回顾性队列研究,纳入61例III/IV期高级别卵巢癌患者,接受新辅助化疗后IDS联合结直肠切除,其中21例(34.4%)联合HIPEC(2017-2020年),40例单纯IDS(2009-2016年)。

主要发现

  • 吻合口漏累积发生率为8.2%(n=5)。
  • HIPEC组吻合口漏发生率为9.5%(n=2),非HIPEC组为7.5%(n=3),差异无统计学意义(p=0.99)。
  • HIPEC组无一例行保护性回肠造口,非HIPEC组有10.0%(n=4)行保护性回肠造口(p=0.29)。
  • 发生吻合口漏的患者总生存期显著缩短(9.4 vs 40.6个月,log-rank p=0.013),无进展生存期无显著差异(12.2 vs 13.3个月,log-rank p=0.31)。

临床怎么用

  • HIPEC不应作为拒绝结直肠切除或决定结肠转流的依据。
  • 需关注吻合口漏对总生存期的负面影响。

局限性

  • 回顾性研究,样本量较小(61例),两组时间跨度不同,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE(S): To evaluate the incidence and associated risk factors for anastomotic failure following interval debulking surgery (IDS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in women with advanced ovarian cancer. METHODS: We performed a retrospective cohort study in women with stage III/IV high-grade ovarian cancer treated with neoadjuvant chemotherapy followed by IDS with colorectal resection and HIPEC from 2017 to 2020. These patients were compared to a historical control cohort who underwent IDS with colorectal resection without HIPEC from 2009 to 2016. Data was collected for demographics, surgical variables, and perioperative outcomes. The univariate analysis compared progression-free survival and overall survival. RESULTS: 61 women were identified; 21 (34.4%) underwent IDS with HIPEC from 2017 to 2020, and 40 underwent IDS alone from 2009 to 2016. None of the patients who had IDS with HIPEC had protective ileostomy, compared to 10.0% of those who received had IDS alone (n = 4)(p = 0.29). The cumulative incidence of anastomotic leak rate was 8.2% (n = 5). There was no significant difference in anastomotic leak rate for women who underwent IDS with HIPEC (9.5%, n = 2) versus without HIPEC (7.5%, n = 3) (p = 0.99). While there was no difference in PFS (12.2 vs. 13.3 months, log-rank p = 0.31), OS (9.4 vs. 40.6 months, log-rank p = 0.013) was significantly decreased following postoperative anastomotic leak. CONCLUSIONS: In this retrospective series of women with advanced ovarian cancer, HIPEC was not associated with increased risk for anastomotic leak at the time of IDS with colorectal resection and reanastomosis. While further study is needed, HIPEC alone should not preclude colorectal resection or dictate practices for colonic diversion in IDS.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Gruner M, Chambers LM, Yao M, et al. Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer. Gynecol Oncol. 2021. PMID: 34247768. doi:10.1016/j.ygyno.2021.06.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。